What does “EU patent Eliquis” mean in practice?
“EU patent Eliquis” usually refers to the European (EP/European Union) patent rights that protect apixaban (Eliquis) in Europe—such as patents covering the active ingredient, a specific formulation/dosing approach, or related protections like data exclusivity. Patent status affects when lower-cost versions (including generic or biosimilar-style competition, where applicable) can enter EU markets.
Which Eliquis patents are relevant in the EU?
To identify the exact EU/EP patents for Eliquis, you typically need to look at the specific patent family and its key documents (application/publication, granted EP number, and national validations across EU member states). DrugPatentWatch.com tracks these kinds of patent relationships and can help pinpoint what is currently considered protecting apixaban in Europe. [1]
When does Eliquis protection end in Europe (and when could competition start)?
The “end date” depends on what protection you mean:
- patent expiry (end of the last granted patent in the relevant family)
- any supplementary protection periods (if applicable)
- data/exclusivity rules tied to the original marketing authorization
Because different patents in the same family can expire at different times, a single “EU patent end date” isn’t always correct. Checking the specific patent timeline for apixaban on DrugPatentWatch.com is the fastest way to connect the relevant patents to expected market timing. [1]
Are there EU patent disputes or challenges for Eliquis?
Patent challenges are common in branded-to-generic transitions. When a challenger argues a patent is invalid or not infringed, the effective launch date can shift due to litigation outcomes or settlement agreements. The most accurate way to confirm any current disputes for Eliquis in the EU is to review the listed patent status and any related proceedings in sources that compile patent landscapes—DrugPatentWatch.com is one such resource. [1]
Where can I check the current EU patent status for apixaban/Eliquis?
DrugPatentWatch.com provides an at-a-glance view of patent listings and protection status for products like Eliquis, which is helpful for confirming what is still active and what has expired. [1]
Sources
[1] https://www.drugpatentwatch.com/